Showing 6231-6240 of 7112 results for "".
- "What Not to Wear" Co-Host Partners with AbbVie on Psoriasis Campaignhttps://practicaldermatology.com/news/20130716-what_not_to_war_co-host_partners_with_abbvie_on_psoriasis_campaign/2459496/Stacy London, of TLC's "What Not to Wear," is partnering with AbbVie on a new psoriasis campaign called <a href="http://www.uncoveryourconfidence.com/">Uncover Your Confidence</a>. The campaign features educational resources and style advice for millions of Americans living with psoriasi
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t
- ASDS Database Helps Residents Find Fellowships and Opportunitieshttps://practicaldermatology.com/news/20130716-asds_database_helps_residents_find_fellowships_and_opportunities/2459499/To help residents with the challenge of identifying suitable fellowship programs, the American Society for Dermatologic Surgery's (ASDS) new database, called the DermSurg Fellowship Finder, is a comprehensive source for all Mohs, procedural, cosmetic, and laser surgical fellowships in the US. The go
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- ASDS Launches Cosmetic Dermatology Fellowship Programhttps://practicaldermatology.com/news/20130627-asds_launches_cosmetic_dermatology_fellowship_program/2459508/The American Society for Dermatologic Surgery (ASDS) launched a fellowship accreditation program designed to promote post-residency training in cosmetic dermatologic surgery procedures. According to ASDS President Timothy C. Flynn, MD, fellowship training will give young dermatologists a solid educa
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials